ERBB2 and inflammatory breast carcinoma: An earlier study of 23 patients with HER2-positive IBC who underwent baseline biopsy and day 8 on-treatment biopsy after loading doses of trastuzumab and pertuzumab found that the gene expression profiles most associated with having a pCR in this population were markers of adaptive immunity, innate immunity, and antigen presentation [34].